Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1110 participants.

Also called NCT01828697

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 1,110 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01828697
  • EudraCT 2012-001505-24
Other papers using this trial's data
  • Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial Lancet (London, England), 2022-11-19 DOI, PubMed 36354038
  • Onset of labor and use of analgesia in women using thromboprophylaxis with 2 doses of low-molecular-weight heparin: insights from the Highlow study Journal of thrombosis and haemostasis : JTH, 2023-01 DOI, PubMed 36695396

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Belgium, Canada, Denmark, France, Ireland, Netherlands, Norway, Russia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01828697. Randomized; no masking; primary purpose prevention. Start 2013-04-24 (actual); primary completion 2021-10-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy
Acronym
Highlow
Condition
Deep Venous Thrombosis
Intervention (Drug)
Low dose nadroparin
Intervention (Drug)
Intermediate dose nadroparin
Intervention (Drug)
Low dose enoxaparin
Intervention (Drug)
Intermediate dose enoxaparin
Intervention (Drug)
Low dose dalteparin
Intervention (Drug)
Intermediate dose dalteparin
Intervention (Drug)
Fixed low dose tinzaparin
Intervention (Drug)
Intermediate dose tinzaparin
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (class: other)
Collaborator
Netherlands Organisation for Scientific Research (class: other government)
Collaborator
Aspen Pharma (class: not stated)
Collaborator
CHU of Saint Etienne: French Ministry of Health Grant (sponsor of the French part of the study) (class: not stated)
Collaborator
Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study)) (class: not stated)

Record details

Record id
cardio:ct-nct01828697
Content hash
e569221cf7b4cd0aa3045a675f4aec8592dee8d0ecb7e6c67812302b94b49094